Antibe Therapeutics (TSX:ATE) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Antibe Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was C$0.01 Mil. Antibe Therapeutics's average total debt for the quarter that ended in Dec. 2023 was C$0.00 Mil. Therefore, Antibe Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was N/A%.

Antibe Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Antibe Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Effective Interest Rate on Debt % Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

23.83

22.37

0.61

3.36

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Antibe Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Antibe Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Effective Interest Rate on Debt % falls into.

Antibe Therapeutics Effective Interest Rate on Debt % Calculation

Antibe Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Mar. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Mar. 2022 )	+	Total Debt (A: Mar. 2023 ))	/ count )
=	-1 * -0.008	/	( (0	+	0)	/ 1 )
=	-1 * -0.008	/	0
=	N/A %

where

	Total Debt (A: Mar. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0
=	0

	Total Debt (A: Mar. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0
=	0

Antibe Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Sep. 2023 )	+	Total Debt (Q: Dec. 2023 ))	/ count )
=	-1 * -0.008	/	( (0	+	0)	/ 1 )
=	-1 * -0.008	/	0
=	N/A %

where

	Total Debt (Q: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0
=	0

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0
=	0

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Antibe Therapeutics (TSX:ATE) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Antibe Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines